cv-9F1B-8F8A-EBE6

publicações selecionadas

• artigo académico

  • Ruthenium(II)-Cyclopentadienyl-Derived Complexes as New Emerging Anti-Colorectal Cancer Drugs.  Pharmaceutics.  2022

• documento

  • Targeting mutated KRAS with PMC79, a new ruthenium drug for pancreatic cancer 2025
  • PMC79: A Novel Ruthenium-Based Therapeutic Targeting Mutant KRAS in Pancreatic Cancer 2025
  • Exploring PMC79 ruthenium agent targeting KRAS mutations in pancreatic cancer 2025
  • PMC79: Um Novo Fármaco de Ruténio que Atua Contra o KRAS Mutado no Cancro do Pâncreas 2025
  • New Iron(II)-Cyclopentadienyl Compounds Show High Therapeutic Potential against Colorectal Cancer Cells 2024
  • New ruthenium-based agents target actin cytoskeleton in colorectal cancer cells 2020